These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 21240463

  • 1. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
    Schedel F, Pries R, Thode B, Wollmann B, Wulff S, Jocham D, Wollenberg B, Kausch I.
    Oncol Rep; 2011 Mar; 25(3):763-8. PubMed ID: 21240463
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma.
    Ekshyyan O, Mills GM, Lian T, Amirghahari N, Rong X, Lowery-Nordberg M, Abreo F, Veillon DM, Caldito G, Speicher L, Glass J, Nathan CO.
    Head Neck; 2010 Dec; 32(12):1619-28. PubMed ID: 20222045
    [Abstract] [Full Text] [Related]

  • 3. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H, Zang C, Schefe JH, Schwarzlose-Schwarck S, Regierer AC, Elstner E, Schulz CO, Scholz C, Possinger K, Eucker J.
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [Abstract] [Full Text] [Related]

  • 4. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma.
    Clark CA, McEachern MD, Shah SH, Rong Y, Rong X, Smelley CL, Caldito GC, Abreo FW, Nathan CO.
    Cancer Prev Res (Phila); 2010 Dec; 3(12):1586-95. PubMed ID: 20851953
    [Abstract] [Full Text] [Related]

  • 5. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.
    Cancer Res; 2005 Nov 01; 65(21):9953-61. PubMed ID: 16267020
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of induced autophagy increases apoptosis of Nara-H cells.
    Nakamura O, Hitora T, Akisue T, Kawamoto T, Yamagami Y, Yamamoto T.
    Int J Oncol; 2011 Dec 01; 39(6):1545-52. PubMed ID: 21805033
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of cyclin D1 by shRNA is associated with enhanced sensitivity to conventional therapies for head and neck squamous cell carcinoma.
    Kothari V, Mulherkar R.
    Anticancer Res; 2012 Jan 01; 32(1):121-8. PubMed ID: 22213296
    [Abstract] [Full Text] [Related]

  • 8. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
    De Martino MC, van Koetsveld PM, Feelders RA, Sprij-Mooij D, Waaijers M, Lamberts SW, de Herder WW, Colao A, Pivonello R, Hofland LJ.
    Endocr Relat Cancer; 2012 Jun 01; 19(3):351-64. PubMed ID: 22420007
    [Abstract] [Full Text] [Related]

  • 9. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 01; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 10. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
    Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY.
    Clin Cancer Res; 2011 Nov 15; 17(22):7116-26. PubMed ID: 21976531
    [Abstract] [Full Text] [Related]

  • 11. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
    Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y.
    Cancer Lett; 2007 Aug 18; 253(2):236-48. PubMed ID: 17360108
    [Abstract] [Full Text] [Related]

  • 12. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
    Grzybowska-Izydorczyk O, Smolewski P.
    Future Med Chem; 2012 Mar 18; 4(4):487-504. PubMed ID: 22416776
    [Abstract] [Full Text] [Related]

  • 13. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H, Cui K, Nie F, Wang L, Brandl MB, Jin G, Li F, Mao Y, Xue Z, Rodriguez A, Chang J, Wong ST.
    Breast Cancer Res Treat; 2012 Jan 18; 131(2):425-36. PubMed ID: 21394501
    [Abstract] [Full Text] [Related]

  • 14. [Effects of mTOR siRNA on mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cells and the growth of transplanted tumor in nude mice].
    Liu MY, Hou GQ, Zhang Y, Bei WJ, Yan AH.
    Zhonghua Zhong Liu Za Zhi; 2011 May 18; 33(5):334-9. PubMed ID: 21875460
    [Abstract] [Full Text] [Related]

  • 15. Centchroman inhibits proliferation of head and neck cancer cells through the modulation of PI3K/mTOR pathway.
    Srivastava VK, Gara RK, Bhatt ML, Sahu DP, Mishra DP.
    Biochem Biophys Res Commun; 2011 Jan 07; 404(1):40-5. PubMed ID: 21094138
    [Abstract] [Full Text] [Related]

  • 16. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
    Xie J, Li Q, Ding X, Gao Y.
    Cell Physiol Biochem; 2018 Jan 07; 46(2):676-686. PubMed ID: 29621758
    [Abstract] [Full Text] [Related]

  • 17. Increased cyclooxygenase-2 expression in human squamous cell carcinomas of the head and neck and inhibition of proliferation by nonsteroidal anti-inflammatory drugs.
    Lee DW, Sung MW, Park SW, Seong WJ, Roh JL, Park B, Heo DS, Kim KH.
    Anticancer Res; 2002 Jan 07; 22(4):2089-96. PubMed ID: 12174888
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.
    Ohara T, Takaoka M, Toyooka S, Tomono Y, Nishikawa T, Shirakawa Y, Yamatsuji T, Tanaka N, Fujiwara T, Naomoto Y.
    Cancer Sci; 2011 Jul 07; 102(7):1344-9. PubMed ID: 21521416
    [Abstract] [Full Text] [Related]

  • 19. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C, Faber A, Umbreit C, Birk R, Weiss C, Sommer JU, Hörmann K, Schultz JD.
    Anticancer Res; 2015 Apr 07; 35(4):1951-9. PubMed ID: 25862847
    [Abstract] [Full Text] [Related]

  • 20. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S.
    Cancer Chemother Pharmacol; 2008 Jul 07; 62(2):305-13. PubMed ID: 17912526
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.